thrasher, as you have identified, starpharma seems to have a number of opportunities to develop over the comings 12-24 months.
These will require funding. Any and all revenue will be banked and earmarked as growth capital. There will be no capital returns (dividends nor buybacks) for the foreseeable future.
Looking Forward, page-2
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
-0.005(4.35%) |
Mkt cap ! $45.32M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $62.84K | 565.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10428 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
11.0¢ |
Change
-0.005 ( 4.35 %) |
||||
| Open | High | Low | Volume | ||
| 11.0¢ | 11.5¢ | 11.0¢ | 167020 | ||
| Last updated 15.32pm 24/05/2024 ? | |||||
| SPL (ASX) Chart |